These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29527204)

  • 1. Clinical, Immunological, and Molecular Findings in Five Patients with Major Histocompatibility Complex Class II Deficiency from India.
    Aluri J; Gupta M; Dalvi A; Mhatre S; Kulkarni M; Hule G; Desai M; Shah N; Taur P; Vedam R; Madkaikar M
    Front Immunol; 2018; 9():188. PubMed ID: 29527204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC-II Deficiency Among Egyptians: Novel Mutations and Unique Phenotypes.
    El Hawary RE; Mauracher AA; Meshaal SS; Eldash A; Abd Elaziz DS; Alkady R; Lotfy S; Opitz L; Galal NM; Boutros JA; Pachlopnik Schmid J; Elmarsafy AM
    J Allergy Clin Immunol Pract; 2019 Mar; 7(3):856-863. PubMed ID: 30170160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC class II expression through a hitherto unknown pathway supports T helper cell-dependent immune responses: implications for MHC class II deficiency.
    Buch T; Polic B; Clausen BE; Weiss S; Akilli-Ozturk O; Chang CH; Flavell R; Schulz A; Jonjic S; Waisman A; Förster I
    Blood; 2006 Feb; 107(4):1434-44. PubMed ID: 16254146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels.
    Schmetterer KG; Seidel MG; Körmöczi U; Rottal A; Schwarz K; Matthes-Martin S; Steinberger P; Pickl WF
    Int Arch Allergy Immunol; 2010; 152(4):390-400. PubMed ID: 20197681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections.
    Renella R; Picard C; Neven B; Ouachée-Chardin M; Casanova JL; Le Deist F; Cavazzana-Calvo M; Blanche S; Fischer A
    Br J Haematol; 2006 Sep; 134(5):510-6. PubMed ID: 16848795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, Immunological, and Molecular Findings in 57 Patients With Severe Combined Immunodeficiency (SCID) From India.
    Aluri J; Desai M; Gupta M; Dalvi A; Terance A; Rosenzweig SD; Stoddard JL; Niemela JE; Tamankar V; Mhatre S; Bargir U; Kulkarni M; Shah N; Aggarwal A; Lashkari HP; Krishna V; Govindaraj G; Kalra M; Madkaikar M
    Front Immunol; 2019; 10():23. PubMed ID: 30778343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients.
    Ouederni M; Vincent QB; Frange P; Touzot F; Scerra S; Bejaoui M; Bousfiha A; Levy Y; Lisowska-Grospierre B; Canioni D; Bruneau J; Debré M; Blanche S; Abel L; Casanova JL; Fischer A; Picard C
    Blood; 2011 Nov; 118(19):5108-18. PubMed ID: 21908431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell transplantation and other management strategies for MHC class II deficiency.
    Picard C; Fischer A
    Immunol Allergy Clin North Am; 2010 May; 30(2):173-8. PubMed ID: 20493394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.
    Prod'homme T; Dekel B; Barbieri G; Lisowska-Grospierre B; Katz R; Charron D; Alcaide-Loridan C; Pollack S
    Immunogenetics; 2003 Nov; 55(8):530-9. PubMed ID: 14574520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency.
    Villard J; Lisowska-Grospierre B; van den Elsen P; Fischer A; Reith W; Mach B
    N Engl J Med; 1997 Sep; 337(11):748-53. PubMed ID: 9287230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation in the class II trans-activator leading to a mild immunodeficiency.
    Wiszniewski W; Fondaneche MC; Le Deist F; Kanariou M; Selz F; Brousse N; Steimle V; Barbieri G; Alcaide-Loridan C; Charron D; Fischer A; Lisowska-Grospierre B
    J Immunol; 2001 Aug; 167(3):1787-94. PubMed ID: 11466404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MHC class II deficiency: Report of a novel mutation and special review.
    Farrokhi S; Shabani M; Aryan Z; Zoghi S; Krolo A; Boztug K; Rezaei N
    Allergol Immunopathol (Madr); 2018; 46(3):263-275. PubMed ID: 28676232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
    Steimle V; Otten LA; Zufferey M; Mach B
    Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct genetic correction as a new method for diagnosis and molecular characterization of MHC class II deficiency.
    Matheux F; Ikinciogullari A; Zapata DA; Barras E; Zufferey M; Dogu F; Regueiro JR; Reith W; Villard J
    Mol Ther; 2002 Dec; 6(6):824-9. PubMed ID: 12498778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined immunodeficiency with defective expression in MHC class II genes.
    Griscelli C; Lisowska-Grospierre B; Mach B
    Immunodefic Rev; 1989; 1(2):135-53. PubMed ID: 2517209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
    Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
    J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, Immunological, and Genetic Findings in Iranian Patients with MHC-II Deficiency: Confirmation of c.162delG RFXANK Founder Mutation in the Iranian Population.
    Mousavi Khorshidi MS; Seeleuthner Y; Chavoshzadeh Z; Behfar M; Hamidieh AA; Alimadadi H; Sherkat R; Momen T; Behniafard N; Eskandarzadeh S; Mansouri M; Behnam M; Mahdavi M; Heydarazad Zadeh M; Shokri M; Alizadeh F; Movahedi M; Momenilandi M; Keramatipour M; Casanova JL; Cobat A; Abel L; Shahrooei M; Parvaneh N
    J Clin Immunol; 2023 Nov; 43(8):1941-1952. PubMed ID: 37584719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
    Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
    Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major histocompatibility complex class II deficiency: a clinical review.
    Elhasid R; Etzioni A
    Blood Rev; 1996 Dec; 10(4):242-8. PubMed ID: 9012922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.